LipoCure, a pioneering brand in the field of therapeutics, is dedicated to developing highly-potent treatments using proprietary liposome-based nano-drugs. These innovative drugs possess novel drug-loading capabilities and drug-release mechanisms. LipoCure focuses on addressing the challenges associated with potent drugs used to treat inflammatory diseases, infectious diseases, and cancers, which often come with severe side effects.

By harnessing the power of liposomal delivery technology, bioenergetics, and nano-technology, LipoCure transforms traditional small-molecule drugs into superior nano-drugs. This transformation greatly improves the therapeutic index and overall performance, while minimizing side effects. Professor Barenholz, the co-developer of the renowned anticancer drug Doxil®, is the founder of LipoCure.

With decades of experience in liposomal drug delivery systems, he has dedicated his research efforts to developing more effective and safer therapies. LipoCure's unique platform technology allows for remote drug loading into nano-liposomes and controlled release at the targeted site. This approach enhances permeability and retention (EPR) effect, resulting in significantly improved therapeutic effects and reduced side effects.

LipoCure's treatments have shown promise in treating rheumatoid arthritis, multiple sclerosis, and cancer. For more information about LipoCure and their groundbreaking therapies, please visit lipocurerx. com